Dane M. Newman

Dane M. Newman

Auto-generated profile, based on publicly available information

Dane M. Newman

Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Science Immunology
Verified
Journal Article
Closed access
CGCatarina Gago da Graça
Catarina Gago da Graça
ASAmania A. Sheikh
Amania A. Sheikh
DNDane M. Newman
Dane M. Newman
LWLifen Wen
Lifen Wen
SLSining Li
Sining Li
DUDaniel T. Utzschneider
Daniel T. Utzschneider
Stem-like T cells are attractive immunotherapeutic targets in patients with cancer given their ability to proliferate and differentiate into effector progeny. Thus, identifying T cells with enhanced stemness and understanding their developmental requirements are of broad clinical and therapeutic interest. Here, we demonstrate that during acute infection, the transcriptional regulator inhibitor of DNA binding 3 (ID3) identifies stem-like T cells that are uniquely adapted to generate precursors of exhausted T (Tpex) cells in response to chronic infection or cancer. Expression of ID3 itself enables Tpex cells to sustain T cell responses in chronic infection or cancer, whereas loss of ID3 results in impaired maintenance of CD8 T cell immunity. Furthermore, we demonstrate that interleukin-1 (IL-1) family members, including IL-36β and IL-18, promote the generation of ID3 + T cells that mediate superior tumor control. Overall, we identify ID3 as a common denominator of stem-like T cells in both acute and chronic infections that is specifically required to sustain T cell responses to chronic stimulation.